# TELIX Pharmaceuticals (TLX.AU)

Canonical: https://gigainvestors.com/s/TLX.AU

Analysis as of: 2026-10-16T07:38:39.392Z. 

Listing currency: AUD. Reporting currency: USD.

## Verdict

Not enough history yet

Quality tests for Buy: not passed (profit record: fail; earnings resilience is evidence only). Published buy qualification: no.

Share price: AUD 15.08 per share; close as of 2026-10-15.

## Checklist

### understandable: na

### moat: na

### economics: na

### management: na

### accounting: na

## Holders

## Price story

Down 49% since Jan 2025 · "Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter" (finance.yahoo.com, Sep 2025)

Story as of 2026-10-16T10:00:10.112Z; price observation 2026-10-15.

- 2025-04-22: Telix Reports US$186M Q1 Revenue, Up 62% YOY ([finance.yahoo.com](https://finance.yahoo.com/news/telix-reports-us-186m-q1-081700806.html))

- 2025-10-14: Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded ([finance.yahoo.com](https://finance.yahoo.com/news/telix-reports-us-206m-revenue-065900022.html))

## Owner memo

Memo as of 2026-10-16T08:06:05.509Z.

### How it makes money

Operates in biotechnology; annual sales are USD 803.8 million.

- Source: https://eodhd.com/api/fundamentals/T3X.F.json#2025-12-31 (filed 2026-02-20); FY2025: revenue 803794000; grossProfit 426438000; margin = grossProfit / revenue.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-16); TLX.AU: Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

### Why customers stay

Margins ranged from 53.1% to 65.1% during 2023–25.

- Source: https://eodhd.com/api/fundamentals/T3X.F.json#2023-12-31 (filed 2026-02-20); FY2023: grossProfit / revenue = 62.9%.

- Source: https://eodhd.com/api/fundamentals/T3X.F.json#2024-12-31 (filed 2026-02-20); FY2024: grossProfit / revenue = 65.1%.

- Source: https://eodhd.com/api/fundamentals/T3X.F.json#2025-12-31 (filed 2026-02-20); FY2025: grossProfit / revenue = 53.1%.

### Where the cash goes

Paid no dividends in 3 years.

- Source: https://eodhd.com/api/fundamentals/T3X.F.json#2023-12-31 (filed 2026-02-20); FY2023: growth capex 610963.1299999999; upkeep 6743000; cash acquisitions 995000; owner earnings 3080855.6059999997. Growth capex plus acquisitions / owner earnings = 0.5212717943912624.

- Source: https://eodhd.com/api/fundamentals/T3X.F.json#2024-12-31 (filed 2026-02-20); FY2024: growth capex 15019345.984298008; upkeep 6142727.445701992; cash acquisitions 23195000; owner earnings 31503394.234298006. Growth capex plus acquisitions / owner earnings = 1.2130231333198291.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-20); Dividend observations: [[2023,0],[2024,0],[2025,0]]. Zero only counted when supported by a complete cash-flow statement.

### Are managers owners

Insiders own 15.8% of the company.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-16); TLX.AU SharesStats.PercentInsiders = 15.809999999999999 percentage points; cache date 2026-10-16.

### What the price says

The price is 4.4 times annual sales; cash earnings are negative.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-20); Closing price 15.08 AUD; reporting-to-trading FX 1.4454626926079037; FY2025 annual sales per share 2.37893334911803; price multiple 4.385429967538947. FY2025 cash earnings/share -0.057835326151296315. Closing-price date 2026-10-15.

## Monthly share-price history (AUD per share)

- 2017-11: AUD 0.65 per share

- 2017-12: AUD 0.62 per share

- 2018-01: AUD 0.56 per share

- 2018-02: AUD 0.54 per share

- 2018-03: AUD 0.58 per share

- 2018-04: AUD 0.63 per share

- 2018-05: AUD 0.69 per share

- 2018-06: AUD 0.67 per share

- 2018-07: AUD 0.64 per share

- 2018-08: AUD 0.88 per share

- 2018-09: AUD 0.83 per share

- 2018-10: AUD 0.84 per share

- 2018-11: AUD 0.68 per share

- 2018-12: AUD 0.65 per share

- 2019-01: AUD 0.72 per share

- 2019-02: AUD 0.72 per share

- 2019-03: AUD 0.84 per share

- 2019-04: AUD 0.87 per share

- 2019-05: AUD 1.06 per share

- 2019-06: AUD 1.24 per share

- 2019-07: AUD 1.41 per share

- 2019-08: AUD 1.37 per share

- 2019-09: AUD 1.57 per share

- 2019-10: AUD 1.64 per share

- 2019-11: AUD 1.70 per share

- 2019-12: AUD 1.55 per share

- 2020-01: AUD 1.48 per share

- 2020-02: AUD 1.31 per share

- 2020-03: AUD 1.00 per share

- 2020-04: AUD 1.38 per share

- 2020-05: AUD 1.38 per share

- 2020-06: AUD 1.28 per share

- 2020-07: AUD 1.30 per share

- 2020-08: AUD 1.65 per share

- 2020-09: AUD 1.66 per share

- 2020-10: AUD 1.68 per share

- 2020-11: AUD 3.58 per share

- 2020-12: AUD 3.78 per share

- 2021-01: AUD 3.93 per share

- 2021-02: AUD 3.83 per share

- 2021-03: AUD 4.28 per share

- 2021-04: AUD 3.74 per share

- 2021-05: AUD 4.50 per share

- 2021-06: AUD 6.09 per share

- 2021-07: AUD 5.63 per share

- 2021-08: AUD 6.79 per share

- 2021-09: AUD 6.03 per share

- 2021-10: AUD 6.03 per share

- 2021-11: AUD 6.60 per share

- 2021-12: AUD 7.75 per share

- 2022-01: AUD 6.79 per share

- 2022-02: AUD 4.94 per share

- 2022-03: AUD 4.18 per share

- 2022-04: AUD 4.61 per share

- 2022-05: AUD 4.66 per share

- 2022-06: AUD 4.53 per share

- 2022-07: AUD 7.39 per share

- 2022-08: AUD 6.20 per share

- 2022-09: AUD 4.73 per share

- 2022-10: AUD 6.93 per share

- 2022-11: AUD 7.36 per share

- 2022-12: AUD 7.27 per share

- 2023-01: AUD 7.09 per share

- 2023-02: AUD 6.98 per share

- 2023-03: AUD 6.90 per share

- 2023-04: AUD 10.15 per share

- 2023-05: AUD 11.70 per share

- 2023-06: AUD 11.22 per share

- 2023-07: AUD 11.29 per share

- 2023-08: AUD 11.06 per share

- 2023-09: AUD 11.40 per share

- 2023-10: AUD 8.84 per share

- 2023-11: AUD 10.08 per share

- 2023-12: AUD 10.08 per share

- 2024-01: AUD 11.50 per share

- 2024-02: AUD 12.44 per share

- 2024-03: AUD 12.89 per share

- 2024-04: AUD 15.05 per share

- 2024-05: AUD 18.15 per share

- 2024-06: AUD 18.65 per share

- 2024-07: AUD 19.08 per share

- 2024-08: AUD 18.61 per share

- 2024-09: AUD 20.73 per share

- 2024-10: AUD 20.93 per share

- 2024-11: AUD 24.74 per share

- 2024-12: AUD 24.61 per share

- 2025-01: AUD 29.34 per share

- 2025-02: AUD 28.46 per share

- 2025-03: AUD 26.52 per share

- 2025-04: AUD 27.13 per share

- 2025-05: AUD 26.10 per share

- 2025-06: AUD 24.42 per share

- 2025-07: AUD 21.05 per share

- 2025-08: AUD 14.60 per share

- 2025-09: AUD 14.57 per share

- 2025-10: AUD 16.08 per share

- 2025-11: AUD 15.22 per share

- 2025-12: AUD 11.20 per share

- 2026-01: AUD 10.55 per share

- 2026-02: AUD 10.00 per share

- 2026-03: AUD 13.66 per share

- 2026-04: AUD 15.00 per share

- 2026-05: AUD 13.03 per share

- 2026-06: AUD 16.58 per share

- 2026-07: AUD 14.21 per share

- 2026-08: AUD 15.36 per share

- 2026-09: AUD 15.72 per share

- 2026-10: AUD 15.78 per share

## Annual estimated value (AUD per share)

Historical values use today's bond yield for every fiscal year

Historical values use today's FX rate into trading currency for every fiscal year

Historical values use current restated fundamentals and current commodity classification; they are not point-in-time estimates

## Sources

[Original 20-F filing](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/tlx-20251231.htm); period 2025-12-31, filed 2026-02-20.

Estimates depend on assumptions and are not guarantees or investment advice. Underlying data remains subject to its source licenses; public reading does not grant bulk redistribution rights.